Skip to main content

Advertisement

SpringerLink
Log in

The effect of trimetazidine on preventing contrast-induced nephropathy after cardiac catheterization

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

Trimetazidine has been shown to prevent the risk of contrast-induced nephropathy (CIN) in patients with renal dysfunction undergoing percutaneous coronary intervention (PCI). However, the effect of trimetazidine on CIN in unselected patients is unknown. We aimed to evaluate the effect of trimetazidine on preventing CIN in unselected patients treated with PCI.

Methods

2154 consecutive patients were enrolled and divided into the trimetazidine (n = 529) and non-trimetazidine group (n = 1625). Patients in the trimetazidine group received trimetazidine 20 mg thrice daily starting at least 24 h before the procedure and continuing until discharge. The primary outcome was CIN.

Results

CIN was observed in 197 (9.2%) patients. The incidence of CIN was similar between two groups (9.1% vs. 9.2%, P = 0.947). After adjusting for other potential risk factors, trimetazidine did not significantly reduce the risk of CIN (OR = 0.70, 95% CI 0.46–1.08, P = 0.104). The results remained similar when using the alternate definitions of CIN and different subgroup analysis based on diabetes or chronic kidney disease. In additional, no significant difference between two groups was found with respect to in-hospital major adverse clinical events (1.89% vs. 1.66%, P > 0.05).

Conclusions

Trimetazidine did not exert significant renal protective effect on preventing CIN and in hosptial major adverse clinical events in unselected patients undergoing PCI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, Van Biesen W (2012) A European renal best practice (ERBP) position statement on the kidney disease improving global outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant 27(12):4263–4272

    Article  Google Scholar 

  2. Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G, Veglia F, Fabbiocchi F, Montorsi P, Bartorelli AL (2012) Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (induced diuresis with matched hydration compared to standard hydration for contrast induced nephropathy prevention) trial. JACC Cardiovasc Interv 5(1):90–97

    Article  Google Scholar 

  3. Wilhelm-Leen E, Montez-Rath ME, Chertow G (2017) Estimating the risk of radiocontrast-associated nephropathy. J Am Soc Nephrol 28(2):653–659

    Article  Google Scholar 

  4. Abe M, Morimoto T, Akao M, Furukawa Y, Nakagawa Y, Shizuta S, Ehara N, Taniguchi R, Doi T, Nishiyama K, Ozasa N, Saito N, Hoshino K, Mitsuoka H, Toma M, Tamura T, Haruna Y, Kita T, Kimura T (2014) Relation of contrast-induced nephropathy to long-term mortality after percutaneous coronary intervention. Am J Cardiol 114(3):362–368

    Article  Google Scholar 

  5. Azzalini L, Garciamoll X (2017) On contrast-induced acute kidney injury, risk prediction, and the future of predictive model development. Can J Cardiol 33(6):711–713

    Article  Google Scholar 

  6. Afshar AE, Parikh PB (2018) Prevention of contrast and radiation injury during coronary angiography and percutaneous coronary intervention. Curr Treat Options Cardiovasc Med 20(4):32

    Article  Google Scholar 

  7. Patschan D, Buschmann I, Ritter O (2018) Contrast-induced nephropathy: update on the use of crystalloids and pharmacological measures. Int J Nephrol 5727309:2018. https://doi.org/10.1155/2018/5727309.eCollection

    Article  Google Scholar 

  8. Kallistratos MS, Poulimenos LE, Giannitsi S (2019) Trimetazidine in the prevention of tissue ischemic conditions. Angiology 70(4):291–298

    Article  CAS  Google Scholar 

  9. Aygen B, Celiker H, Dogukan A, Ilhan N (2008) The effects of trimetazidine on lipid peroxidation in patients with end-stage renal disease. Methods Find Exp Clin Pharmacol 30(10):757–760

    Article  CAS  Google Scholar 

  10. Ye Z, Lu H, Su Q, Guo W, Dai W, Li HQ, Hf Yang, Li L (2017) Clinical effect of trimetazidine on prevention of contrast-induced nephropathy in patients with renal insufficiency: an updated systematic review and meta-analysis. Medicine 96(9):e6059

    Article  CAS  Google Scholar 

  11. Ibrahim TA, El-Mawardy RH, El-Serafy AS, El-Fekky EM (2017) Trimetazidine in the prevention of contrast-induced nephropathy in chronic kidney disease. Cardiovasc Revasc Med 18(5):315–319

    Article  Google Scholar 

  12. Rahman MM, Haque SS, Rokeya B, Siddique MA, Banerjee SK, Ahsan SA, Rahman F, Mahmood M, Ahmed K, Bhuiyan MM (2012) Trimetazidine in the prevention of contrast induced nephropathy after coronary angiogram. Mymensingh Med J 21(2):292–299

    CAS  PubMed  Google Scholar 

  13. Liu W, Ming Q, Shen J, Wei Y, Li W, Chen W, Xu Y (2015) Trimetazidine prevention of contrast-induced nephropathy in coronary angiography. Am J Med Sci 350(5):398–402

    Article  Google Scholar 

  14. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612

    Article  Google Scholar 

  15. Stacul F, Aj VDM, Reimer P, Webb JA, Thomsen HS, Morcos SK, Almén T, Aspelin P, Bellin MF, Clement O (2011) Contrast induced nephropathy: updated ESUR contrast media safety committee guidelines. Eur Radiol 21(12):2527–2541

    Article  Google Scholar 

  16. Scharnweber T, Alhilali L, Fakhran S (2017) Contrast-induced acute kidney injury: pathophysiology, manifestations, prevention, and management. Magn Reson Imaging Clin N Am 25(4):743–753

    Article  Google Scholar 

  17. Wang N, Wei RB, Li QP, Yang X, Li P, Huang MJ, Wang R, Cai GY, Chen XM (2015) Renal protective effect of probucol in rats with contrast-induced nephropathy and its underlying mechanism. Med Sci Monit 21:2886–2892

    Article  CAS  Google Scholar 

  18. Steg PG, Grollier G, Gallay P, Morice M, Karrillon GJ, Benamer H, Kempf C, Laperche T, Arnaud P, Sellier P (2001) A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol 77(2):263–273

    Article  CAS  Google Scholar 

  19. Zhang N, Lei J, Liu Q, Huang W, Xiao H, Lei H (2015) The effectiveness of preoperative trimetazidine on myocardial preservation in coronary artery bypass graft patients: a systematic review and meta-analysis. Cardiology 131(2):86–96

    Article  CAS  Google Scholar 

  20. Onbasili AO, Yeniceriglu Y, Agaoglu P, Karul A, Tekten T, Akar H, Discigil Guzel (2007) Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart 93(6):698–702

    Article  CAS  Google Scholar 

  21. Shehata M (2014) Impact of trimetazidine on incidence of myocardial injury and contrast-induced nephropathy in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention. Am J Cardiol 114(3):389–394

    Article  CAS  Google Scholar 

  22. Ye Z, Lu H, Su Q, Xian X, Li L (2017) Effect of trimetazidine on preventing contrast-induced nephropathy in diabetic patients with renal insufficiency. Oncotarget 8(60):102521–102530

    Article  Google Scholar 

  23. Shalansky SJ, Vu T, Pate GE, Levin A, Humphries KH, Webb JG (2012) N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best? Pharmacotherapy 25(8):1095–1103

    Article  Google Scholar 

Download references

Acknowledgements

This study was supported by a Grant from the National Science Foundation for Young Scientists of China (Grant No. 81800325) and Science and Technology Planning Project of Guangzhou City (201906010089), and Medical Science and Technology Research Funding of Guangdong (A2017347), and China Youth Research Funding (2017-CCA-VG-018), and the Medjaden Academy & Research Foundation for Young Scientists (Grant No. MJR20160025). The funders had no role in the study design, data collection and analysis, the decision to publish, or the preparation of the manuscript. The work was not funded by any industry sponsors. All authors agreed to submit the manuscript for publication.

Author information

Author notes

  1. Xingji Lian, Wenfei He and Huimin Zhan have contributed equally to the work.

Authors and Affiliations

  1. Department of Nephrology, Guangdong Provincial Geriatrics Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, 510100, Guangzhou, Guangdong, China

    Xingji Lian

  2. Department of Cardiology, The Second People’s Hospital of Nanhai District, Guangdong Provincial People’s Hospital’s Nanhai Hospital, 528251, Foshan, China

    Wenfei He

  3. Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, 510100, Guangzhou, China

    Huimin Zhan, Jiyan Chen, Ning Tan, Pengcheng He & Yuanhui Liu

Authors
  1. Xingji Lian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wenfei He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Huimin Zhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiyan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ning Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pengcheng He
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuanhui Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Pengcheng He or Yuanhui Liu.

Ethics declarations

Conflict of interest

The authors of the present manuscript have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 17 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lian, X., He, W., Zhan, H. et al. The effect of trimetazidine on preventing contrast-induced nephropathy after cardiac catheterization. Int Urol Nephrol 51, 2267–2272 (2019). https://doi.org/10.1007/s11255-019-02308-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-019-02308-w

Keywords

Search

Navigation